Examining immune responses in advanced lung cancer patients after treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to describe the antitumor immune response in patients with unresectable stage III non-small cell lung cancer (NSCLC) who have received chemoradiotherapy (cCRT) followed by immunotherapy (Durvalumab). It will collect and analyze secondary data from patient clinical charts and blood samples over a three-year period. The study focuses on patients who have not progressed after cCRT and are treated according to standard clinical practices. The goal is to understand how these treatments interact and affect immune responses in real-world settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with histologically- or cytologically- documented NSCLC who present unresectable stage IIIA-IIIB-IIIC disease, according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology).
* ECOG 0-1.
* PDL1\>1%.
* Age ≥ 18 years at time of study
* Patients without progression after cCRT, that are going to receive IO treatment (Durvalumab) for 12 months as subsequent treatment as per standard clinical practice
* Patient capable of proper therapeutic compliance and accessible for correct follow-up.
* Patients must have signed, dated and IRB/EC-approved written informed consent form in accordance with regulatory and institutional guidelines.

Exclusion Criteria:

* Patients who refuse to sign and date an IRB/IEC-approved written informed consent form.
* No possibility of venipuncture
* Any medical, mental, or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or understand the patient information.

Where it's running

• Complejo Hospitalario Universitario Del Ferrol
  Ferrol, A Coruña, Spain Recruiting
• Hospital General Universitario de Alicante
  Alicante, Alicante, Spain Recruiting
• ICO Badalona, Hospital Germans Trias i Pujol
  Badalona, Barcelona, Spain Recruiting
• Hospital Universitari Vall d' Hebron
  Barcelona, Barcelona, Spain Recruiting
• Hospital de la Santa Creu i Sant Pau
  Barcelona, Barcelona, Spain Recruiting
• Hospital De Basurto
  Bilbao, Bilbao, Spain Recruiting

Study contacts

• Study coordinator: Eva Pereira
• Email: gecp@gecp.org
• Phone: +34934302006

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BL-B01D1 plus osimertinib vs osimertinib alone in unresectable EGFR-mutated NSCLC (Stage III) after chemoradiation

  This trial tests whether adding BL-B01D1 to osimertinib helps people with unresectable Stage III EGFR-mutated non-small cell lung cancer who did not progress after platinum-based chemoradiation.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT07640789

• Pulmonary rehabilitation for people who survived advanced non-small cell lung cancer

  This research will try an eight-week pulmonary rehabilitation program to see if it helps people with advanced non-small cell lung cancer breathe easier and have more energy.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT07104630

• Chemoradiotherapy followed by durvalumab for stage III lung cancer

  This study is testing if giving a combination of chemotherapy, radiation, and the immunotherapy durvalumab can help people with stage III lung cancer who couldn't initially have surgery, to see if it improves their chances of survival.

  Recruiting Phase 4 Amsterdam UMC, location VUmc · Amsterdam · NCT06908070

• New treatment for advanced non-small-cell lung cancer using a virus and chemotherapy

  This study is testing a new treatment that combines a special virus and chemotherapy to see if it can help people with advanced lung cancer who haven't responded to previous treatments.

  Recruiting at 15 sites Phase 2 Genelux Corporation · Bullhead City, Arizona and 14 other locations · NCT06463665

• Neoadjuvant treatment for advanced lung cancer with lymph node involvement

  This study is testing if a new treatment combining an immunotherapy drug and chemotherapy can help people with advanced lung cancer that has spread to lymph nodes do better before and after surgery.

  Recruiting at 3 sites Phase 2 Georgetown University · Washington D.C., District of Columbia and 2 other locations · NCT06449313

• Using 177Lu-anti-PD-L1 for treating metastatic solid tumors

  This study is testing a new treatment called 177Lu-RAD204 to see if it can safely help people with advanced solid tumors like lung cancer and melanoma.

  Recruiting at 4 sites Early Phase 1 Radiopharm Theranostics, Ltd · Gosford, New South Wales and 5 other locations · NCT06305962

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.